UplighTED are ongoing randomized, double-blinded, placebo-controlled, parallel-group, 2-arm, international, multicenter, phase 3 trials aiming to assess the efficacy, safety/tolerability, PK/PD, and immunogenicity of efgartigimod PH20 SC in adults with TED. UplighTED will assess clinical outcomes, disease course, and QoL outcomes over 24 weeks in ~108 participants with TED across each of the 2 studies.
